GT Biopharma Inc Total Liabilities
GT Biopharma Inc total liabilities. Based on the latest financial reports, GT Biopharma Inc (GTBP) has total liabilities worth $2.22 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check GT Biopharma Inc (GTBP) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of GT Biopharma Inc (1983–2025)
Total liabilities of GT Biopharma Inc from 1983 to 2025. This chart illustrates how GT Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data.
GT Biopharma Inc Competitors by Total Liabilities
The table below lists competitors of GT Biopharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhuhai Sailong Pharmaceutical Co Ltd
SHE:002898
|
China | CN¥477.34 Million |
|
Flux Power Holdings Inc
NASDAQ:FLUX
|
USA | $33.02 Million |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $1.60 Million |
|
Platinex Inc
F:9PX
|
Germany | €3.30 Million |
|
Tian An Australia Ltd
AU:TIA
|
Australia | AU$188.16 Million |
|
Mainz Biomed BV
NASDAQ:MYNZ
|
USA | $4.69 Million |
|
Intanwijaya Internasional Tbk
JK:INCI
|
Indonesia | Rp73.38 Billion |
|
Cuscapi Berhad
KLSE:0051
|
Malaysia | RM21.42 Million |
Liability Composition Analysis (1983–2025)
This chart breaks down GT Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GT Biopharma Inc balance sheet assets.
Liquidity & Leverage Metrics
GT Biopharma Inc Total Liabilities Ratios Explained
GT Biopharma Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GT Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GT Biopharma Inc (1983–2025)
The table below shows the annual total liabilities of GT Biopharma Inc from 1983 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.32 Million | -60.71% |
| 2024-12-31 | $5.90 Million | -11.02% |
| 2023-12-31 | $6.63 Million | +32.61% |
| 2022-12-31 | $5.00 Million | -51.24% |
| 2021-12-31 | $10.26 Million | -70.77% |
| 2020-12-31 | $35.09 Million | +78.09% |
| 2019-12-31 | $19.71 Million | +40.47% |
| 2018-12-31 | $14.03 Million | +423.67% |
| 2017-12-31 | $2.68 Million | -85.86% |
| 2016-12-31 | $18.95 Million | -62.57% |
| 2015-12-31 | $50.62 Million | +66.18% |
| 2014-12-31 | $30.46 Million | +370.02% |
| 2013-12-31 | $6.48 Million | -1.23% |
| 2012-12-31 | $6.56 Million | +25.47% |
| 2011-12-31 | $5.23 Million | -7.50% |
| 2010-12-31 | $5.65 Million | -20.46% |
| 2009-12-31 | $7.11 Million | +66.46% |
| 2008-12-31 | $4.27 Million | +32.28% |
| 2007-12-31 | $3.23 Million | -58.63% |
| 2006-12-31 | $7.80 Million | +82.80% |
| 2005-12-31 | $4.27 Million | +59.25% |
| 2004-12-31 | $2.68 Million | +145.20% |
| 2003-12-31 | $1.09 Million | +42.50% |
| 2002-12-31 | $767.00K | -35.44% |
| 2001-12-31 | $1.19 Million | -23.45% |
| 2000-12-31 | $1.55 Million | -37.80% |
| 1999-12-31 | $2.50 Million | -37.63% |
| 1998-12-31 | $4.00 Million | -31.03% |
| 1997-12-31 | $5.80 Million | +65.71% |
| 1996-12-31 | $3.50 Million | -37.50% |
| 1995-12-31 | $5.60 Million | +24.44% |
| 1994-12-31 | $4.50 Million | +1400.00% |
| 1993-12-31 | $300.00K | -50.00% |
| 1992-12-31 | $600.00K | +200.00% |
| 1991-12-31 | $200.00K | 0.00% |
| 1990-12-31 | $200.00K | -60.00% |
| 1989-12-31 | $500.00K | +66.67% |
| 1988-12-31 | $300.00K | +50.00% |
| 1987-12-31 | $200.00K | -60.00% |
| 1986-12-31 | $500.00K | +400.00% |
| 1985-12-31 | $100.00K | -66.67% |
| 1984-12-31 | $300.00K | -25.00% |
| 1983-12-31 | $400.00K | -- |
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, tha… Read more